Status:
WITHDRAWN
FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 Study
Lead Sponsor:
Andrew Krystal
Collaborating Sponsors:
Yale University
Conditions:
Anxiety Disorders
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
Brief Summary
The available treatments for patients with mood and anxiety spectrum disorders have significant limitations. This study will contribute significantly to public health by taking steps to address these ...
Detailed Description
This study is an open-label study of two weeks of daily dosing of LY2456302 carried out in 10 healthy volunteers. Subjects will have an initial screening visit where they will have the opportunity to ...
Eligibility Criteria
Inclusion
- Age 21 through 65 years of age
- Body mass index 19 through 30 lbs/in2
- Reliable and willing to be available for the duration of the study
- Willing and able to give written informed consent to participate
- Able to understand and comply with instructions
- If female of childbearing potential, must agree to use dual methods of contraception and be willing and able to continue contraception for 6 weeks after the last dose of study drug. Females using oral contraception must have started using it at least 2 months prior to the Baseline Visit
- If male of childbearing potential, must have undergone surgical sterilization (such as a vasectomy) or agree to use a condom used with a spermicide during participation in the study and for 1 month afterward
Exclusion
- Any clinically significant abnormality of any of the hematology, clinical, chemistry, or urine drug tests
- Magnetic resonance imaging contraindications at 3 Tesla (e.g., ferromagnetic implants or shrapnel or other incompatibilities)
- Any clinically significant abnormality of the 12-lead ECG; QTc (corrected QT) interval recorded on screening or predose greater than 450 msec
- Any clinically significant history of neurologic disease, cancer, or cardiac, respiratory, metabolic, hepatic, renal, gastrointestinal (except appendectomy), dermatological, venereal, hematological disorder or disease
- Any clinically significant history of Axis I psychiatric disorder, or history of attempted suicide
- History of seeking advice from a physician or counselor for abuse or misuse of alcohol, non-medical drugs, medicinal drugs or other substance abuse, for example, solvents
- Any current or previous recreational use of Class A drugs such as opiates, cocaine, ecstasy, LSD (Lysergic acid diethylamide), and amphetamines (Class B)
- Positive drugs-of-abuse test result at initial exam or at any time during the study
- An alcoholic intake greater than 7 units per week or unwillingness to stop alcohol consumption for the duration of the study {1 unit = 8 g ethanol (250 mL of beer, 1 glass wine \[100 mL\], 1 measure spirits \[30 mL\])}
- Use of prescribed medication within 30 days of the first study day, or nonprescription medication including herbal remedies except standard dose vitamin supplements and acetaminophen (up to 4 g/day) within 15 days of the first study drug administration, or any medication that would need to be continued during the study
- Use of any investigational medication within 3 months prior to the start of this study or scheduled to receive an investigational drug other than LY2456302 during the course of this study
- Any smoking of cigarettes or use of any nicotine containing products within the last month or at any time during the study
- History of blood donation in the last 3 months
- History of severe allergies or multiple adverse drug reactions
- Known hypersensitivity to LY2456302
- Any history of a clinically significant gastrointestinal condition
- Any other condition that in the opinion of the investigator would preclude participation in the study
- Pregnant or lactating
- History of peptic ulcer disease or gastritis or positive urea breath test
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2015
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02218775
Start Date
October 1 2014
End Date
April 1 2015
Last Update
May 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University
New Haven, Connecticut, United States, 06510